摘要
Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), and reducing sorafenib resistance is an important issue to be resolved for the clinical treatment of HCC. In the current study, we identified that ABCC5 is a critical regulator and a promising therapeutic target of acquired sorafenib resistance in human hepatocellular carcinoma cells. The expression of ABCC5 was dramatically induced in sorafenib-resistant HCC cells and was remarkably associated with poor clinical prognoses. The down-regulation of ABCC5 expression could significantly reduce the resistance of sorafenib to HCC cells. Importantly, activation of PI3K/AKT/NRF2 axis was essential for sorafenib to induce ABCC5 expression. ABCC5 increased intracellular glutathione (GSH) and attenuated lipid peroxidation accumulation by stabilizing SLC7A11 protein, which inhibited ferroptosis. Additionally, the inhibition of ABCC5 enhanced the anti-cancer activity of sorafenib in vitro and in vivo . These findings demonstrate a novel molecular mechanism of acquired sorafenib resistance and also suggest that ABCC5 is a new regulator of ferroptosis in HCC cells.
学科与关键词
- FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinomaTan, Xiang-Peng; Xiong, Ben-Han; Zhang, Yuan-Xu; Wang, Shen-Li; Zuo, Qian*; Li, Jing*European Journal of Pharmacology, 2022, 931: 175186.被引 5
- Downregulation of MCF2L Promoted the Ferroptosis of Hepatocellular Carcinoma Cells through PI3K/mTOR Pathway in a RhoA/Rac1 Dependent MannerHuang, Si-cong; Chen, Yi-mei; Hu, Ying-yu; Shi, Yong-jie; Xiao, Qi-wen; Li, Zhe; Kang, Jia-le; Zhou, Qiang; Shen, Gang*; Jia, Hong-yun*DISEASE MARKERS, 2022, 2022: 6138941.被引 3
- Fe3+-binding transferrin nanovesicles encapsulating sorafenib induce ferroptosis in hepatocellular carcinomaXiao, Youmei; Xu, Zhanxue; Cheng, Yuan; Huang, Rufan; Xie, Yuan; Tsai, Hsiang-i; Zha, Hualian; Xi, Lifang; Wang, Kai; Cheng, Xiaoli; Gao, Yanfeng; Zhang, Changhua*; Cheng, Fang*; Chen, Hongbo*BIOMATERIALS RESEARCH, 2023, 27(1): 63.被引 5
